TY - JOUR
T1 - Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia
T2 - A report from the Children's Oncology Group
AU - Matloub, Yousif
AU - Bostrom, Bruce C.
AU - Hunger, Stephen P.
AU - Stork, Linda C.
AU - Angiolillo, Anne
AU - Sather, Harland
AU - La, Mei
AU - Gastier-Foster, Julie M.
AU - Heerema, Nyla A.
AU - Sailer, Scott
AU - Buckley, Patrick J.
AU - Thomson, Blythe
AU - Cole, Catherine
AU - Nachman, James B.
AU - Reaman, Gregory
AU - Winick, Naomi
AU - Carroll, William L.
AU - Devidas, Meenakshi
AU - Gaynon, Paul S.
PY - 2011/7/14
Y1 - 2011/7/14
N2 - Children's Cancer Group-1991 selected 2 components from the Children's Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.
AB - Children's Cancer Group-1991 selected 2 components from the Children's Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.
UR - http://www.scopus.com/inward/record.url?scp=79960462879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960462879&partnerID=8YFLogxK
U2 - 10.1182/blood-2010-12-322909
DO - 10.1182/blood-2010-12-322909
M3 - Article
C2 - 21562038
AN - SCOPUS:79960462879
SN - 0006-4971
VL - 118
SP - 243
EP - 251
JO - Blood
JF - Blood
IS - 2
ER -